CNS prophylaxis in diff use large B-cell lymphoma

摘要

In the randomised LNH03-2B trial (Nov 26, p 1858),1 Christian Recher and colleagues report that intensified immunochemotherapy (rituximab, doxorubicin, cyclophosphamide, vin-desine, bleomycin, and prednisone [R-ACVBP]) as first-line treatment for diffuse large B-cell lymphoma significantly improved event-free and overall survival compared with the present standard therapy (rituximab, cyclophosphamide, doxorubicin, vin-cristine, and prednisone [R-CHOP]) at the expense of highertoxic effects and costs for supportive care.